As Chief Financial Officer (CFO) of MorphoSys, Lukas Gilgen brings over 20 years of experience leading finance teams and supporting significant M&A transactions. In this role, Lukas oversees financial operations and facilitates the integration of MorphoSys into Novartis.

Prior to joining MorphoSys, Lukas served as Transaction Lead Enterprise Projects at Novartis within the company’s global Finance function, where he led the successful spin-off of the Biosimilars and Generics Division, Sandoz, and other divestments by Novartis. He was previously a Group Financial Controller at Novartis and has held various finance roles at the company throughout his career. Additionally, Lukas served as the Country CFO Switzerland of Alcon, the former eye care division of Novartis, from 2012-2016.

Lukas holds a Master of Arts in Business Administration and Economics from the University of St. Gallen.